Hyderabad, India-based Bharat Biotech, announced a partnership with Spanish biopharmaceutical company BioFabri to develop, manufacture and distribute a new tuberculosis vaccine. MTBVAC, a live attenuated vaccine, is considered one of the most promising vaccine candidates in the current global TB vaccine pipeline.
Biofabri is part of the Zendal Group based in Porriño, Spain, which researches, develops and manufactures vaccines. The vaccine will be manufactured and developed by Biofabri in collaboration with the University of Zaragoza, The International AIDS Vaccine Initiative, and the Tuberculosis Vaccine Initiative.
The partnership between Bharat Biotech and Biofabri will guarantee worldwide production and the supply of the future vaccine in more than 70 countries in South East Asia and sub-Saharan Africa.
“We are proud to announce this partnership with BioFabri, where MTBVAC can become a global TB vaccine. Bharat Biotech has opted for this vaccine candidate owing to its advanced stage of clinical development as well as the extremely promising results from Phase 1 and Phase 2 clinical trials,” said Dr Krishna Ella, chairman and managing director, Bharat Biotech.
“The experience of Bharat will be a great help reinforcing collaboration with the International AIDS Vaccine Initiative, and the Tuberculosis Vaccine Initiative,” said Professor Martin, the principal investigator of TB Vaccine project at the University of Zaragoza.
Last updated: December 26th, 2025
